CINECA IRIS Institutional Research Information System

ANTONIOTTI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.293
AS - Asia 3.912
EU - Europa 2.473
SA - Sud America 791
AF - Africa 185
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 14.664
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.105
SG - Singapore 1.410
CN - Cina 919
IT - Italia 850
HK - Hong Kong 824
BR - Brasile 640
SE - Svezia 303
DE - Germania 292
VN - Vietnam 259
BG - Bulgaria 228
GB - Regno Unito 180
RU - Federazione Russa 122
CA - Canada 116
IN - India 107
FI - Finlandia 103
FR - Francia 95
AT - Austria 66
TR - Turchia 64
JP - Giappone 62
CI - Costa d'Avorio 58
KR - Corea 53
AR - Argentina 50
NL - Olanda 48
BD - Bangladesh 43
UA - Ucraina 39
MX - Messico 36
PL - Polonia 36
IQ - Iraq 28
ID - Indonesia 27
EC - Ecuador 25
ZA - Sudafrica 25
ES - Italia 24
SN - Senegal 24
NG - Nigeria 23
BE - Belgio 19
UZ - Uzbekistan 18
SA - Arabia Saudita 16
VE - Venezuela 16
CZ - Repubblica Ceca 15
PY - Paraguay 14
CO - Colombia 12
PE - Perù 12
PK - Pakistan 12
EG - Egitto 11
IE - Irlanda 11
CL - Cile 10
MA - Marocco 9
PH - Filippine 9
TN - Tunisia 9
KE - Kenya 8
UY - Uruguay 8
DZ - Algeria 7
IL - Israele 7
LT - Lituania 7
PT - Portogallo 6
JM - Giamaica 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AO - Angola 4
AZ - Azerbaigian 4
BB - Barbados 4
BO - Bolivia 4
CH - Svizzera 4
CR - Costa Rica 4
GT - Guatemala 4
JO - Giordania 4
MY - Malesia 4
NP - Nepal 4
PA - Panama 4
RO - Romania 4
TT - Trinidad e Tobago 4
AU - Australia 3
BY - Bielorussia 3
DK - Danimarca 3
KH - Cambogia 3
LB - Libano 3
LK - Sri Lanka 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BF - Burkina Faso 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
LY - Libia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AI - Anguilla 1
BJ - Benin 1
EE - Estonia 1
GH - Ghana 1
HU - Ungheria 1
IR - Iran 1
Totale 14.649
Salva come PNG Salva come JPEG
Città #
Hong Kong 814
Ashburn 795
Woodbridge 761
Singapore 707
Santa Clara 587
Fairfield 536
Chandler 470
Dallas 470
Houston 413
Ann Arbor 401
Seattle 257
Shanghai 247
Sofia 228
Wilmington 210
New York 203
Cambridge 191
Beijing 169
Boardman 147
Los Angeles 127
Milan 112
Princeton 112
Lawrence 102
Pisa 101
Medford 86
Hefei 81
Florence 79
London 76
Ottawa 74
Munich 68
Des Moines 67
Ho Chi Minh City 63
Abidjan 58
Vienna 56
Dearborn 50
Buffalo 49
Seoul 48
São Paulo 46
Düsseldorf 44
Tokyo 44
Dong Ket 41
Cascina 40
Redondo Beach 40
Ogden 39
San Diego 37
Rome 36
Frankfurt am Main 34
Nanjing 34
Istanbul 33
Bremen 32
Turin 31
Warsaw 31
Genoa 28
Helsinki 28
Turku 27
Hanoi 25
Dakar 24
Lagos 23
Serra 22
Redwood City 21
Nuremberg 20
Boulder 19
Phoenix 19
Rio de Janeiro 19
Brussels 18
Chicago 18
Kunming 17
Fuzhou 16
Montreal 16
Mumbai 16
Jacksonville 15
Guangzhou 14
Izmir 14
Pune 14
Seacroft 14
Shenyang 14
Tashkent 14
Atlanta 12
Chennai 12
Dhaka 12
Haiphong 12
Marseille 12
Nanchang 12
San Jose 12
Toronto 12
Manchester 11
San Francisco 11
Stockholm 11
Baghdad 10
Belo Horizonte 10
Boston 10
Brasília 10
Hebei 10
Johannesburg 10
Brooklyn 9
Dublin 9
Jakarta 9
Orem 9
Poplar 9
Amsterdam 8
Changsha 8
Totale 10.302
Salva come PNG Salva come JPEG
Nome #
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 209
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 197
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 192
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
TAS-102 for the treatment of metastatic colorectal cancer 172
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 169
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 169
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 168
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 168
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 163
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 159
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 159
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 157
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 156
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 150
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 148
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 148
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 147
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 146
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 144
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 142
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 141
A still missing piece of the FIRE-3 puzzle 140
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 138
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 137
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 137
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 136
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 135
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 134
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 134
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 134
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 134
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 133
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 131
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 130
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 129
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. 129
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer 129
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 127
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 127
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 127
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 124
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 123
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 122
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 122
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 121
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 121
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 121
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 121
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 118
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 118
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. 118
Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. 117
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 117
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 117
prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 116
Primary tumor location is a major independent prognostic factor for mcrc patients. 115
Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). 115
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 114
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 113
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). 113
Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV). 113
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 112
null 111
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 111
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 110
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? 110
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 109
null 109
FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. 107
Ksr1 gene polymorphism in mcrc patients treated with first-line folfiri and bevacizumab. 106
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 105
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. 104
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 104
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 104
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? 102
KSR1 gene polymorphism in MCRC patients treated with first-line folfiri and bevacizumab. 102
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 102
Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study 101
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. 101
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 98
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 98
Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. 97
The winding roadmap of biomarkers toward clinic: Lessons from predictors of resistance to anti-EGFRs in metastatic colorectal cancer 92
null 91
null 90
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 90
Prospective study of EGFR intron 1 ca tandem repeats as predictive factor of benefit from cetuximab and irinotecan. 89
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 89
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm 88
Prospective evaluation of candidate snps of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients treated with first-line folfiri plus bevacizumab (BV). 88
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 88
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 88
Totale 12.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021459 0 0 0 0 0 0 52 44 110 51 47 155
2021/2022972 25 24 23 18 162 171 18 32 54 72 72 301
2022/20231.422 170 193 88 126 138 200 15 86 235 23 131 17
2023/20241.193 75 96 202 81 146 178 98 45 27 39 85 121
2024/20254.285 86 139 70 179 397 488 328 197 424 506 435 1.036
2025/20263.107 378 627 592 543 526 439 2 0 0 0 0 0
Totale 14.971